Evotec AG, a Hamburg, Germany-based drug discovery and development company, has formed a collaboration with Carna Biosciences, a Kobe, Japan-based biopharmaceutical company, to use Evotec’s INDiGO platform to develop Carna’s investigational blood cancer drug (CB-1763) up to Carna’s investigational new drug application (IND) submission with the US Food and Drug Administration.

Evotec’s INDiGO platform accelerates early drug candidates into the clinic by reducing time from nomination to regulatory submission in 52 weeks, according to information from Evotec. Evotec gained the platform as part of its 2017 acquisition of Aptuit, a Greenwich, Connecticut-based pharmaceutical services company.

In addition to CB-1763, Carna has another reversible Bruton’s tyrosine kinase (BTK) inhibitor in preclinical development, AS-871, a non-covalent BTK inhibitor targeting autoimmune diseases. AS-871 is also undergoing IND-enabling studies in collaboration with Evotec.

Source: Evotec AG